Comprehensive safety assessments were performed and efficacy analyses included the proportions of patients in clinical remission ( CD Activity Index ( CDAI ) < @ and no treatment failure ( TF ) ) , and with a clinical response ( @ or @ point CDAI reduction from baseline or remission and no TF ) .